IP Library Granted Patent US 12,655,286
Granted Patent B2
US 12,655,286 · App. 18/242,706 · Granted Jun 16, 2026

Grafted polymer and use thereof

Inventors: James Anthony DiBella, Jr. (Macedon, NY); Alok Kumar Awasthi (Pittsford, NY); Jade J. Russell (Perry, NY); Mark R. Mis (Rush, NY); James Hauenstein (Williamson, NY); Mark Fornalik (Webster, NY); Andrew J. Hoteling (Ontario, NY); Shawn M. Conlon (Webster, NY); Kaushlendra Kumar (Bangalore, IN)
Assignee: BAUSCH + LOMB IRELAND LIMITED
C08L51/02A61L12/086A61L26/0023C08K5/053G02B1/043C08L71/02C08L2201/08C08L2312/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,655,286
App. No.
18/242,706
Granted
Jun 16, 2026
Kind
B2
Abstract

A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

Claims (31)

1 . A biomedical device having a coating on a surface thereof, the coating comprising a grafted glycosaminoglycan polymer,

wherein the grafted glycosaminoglycan polymer is a reaction product of (a) a glycosaminoglycan having a polymer backbone containing reactive functionalities; and (b) a polymer comprising polyalkylene glycol chains and at least one reactive end group complementary to at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan; wherein the at least one reactive end group of the polymer forms one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan, wherein the reaction product is derived from (i) activating the glycosaminoglycan in a solution comprising one or more catalysts with an activator comprising one or more epoxyamines; and (ii) grafting the one or more side chains comprising the polyalkylene glycol-containing residue onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan by sequentially or simultaneously adding a polyol and an epoxyalcohol to the activated glycosaminoglycan; and

wherein the biomedical device is a contact lens or an intraocular lens.

2 . The biomedical device according to claim 1 , wherein the glycosaminoglycan is selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, hyaluronan, and hyaluronic acid or a salt thereof.

3 . The biomedical device according to claim 1 , wherein the polyalkylene glycol-containing residue is derived from a polymer or a salt thereof having the following structure:

Z-(((CH 2 ) a —O) b ) c —Y

wherein Z is a reactive or non-reactive end-capped group, Y is reactive functional end group, a is from 2 to 6, b is from 2 to 10,000 and c is 1 or 2.

4 . The biomedical device according to claim 3 , wherein Z is selected from the group consisting of an alkoxy group, a hydroxyl group, a glycidyl group, a thiol group and an amine group, and Y is selected from the group consisting of —X—NH 2 , —X-polydimethylsiloxane-NH 2 , —X—SH, and —X—C(O)—R′ wherein X is a linker group and R′ is hydrogen or an organic moiety comprised of 1 to 20 carbon atoms.

5 . A packaging system for the storage of an ophthalmic device comprising a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising a grafted glycosaminoglycan polymer comprising a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone, wherein the aqueous packaging solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 9 and is sterilized.

6 . The packaging system according to claim 5 , wherein the polyalkylene glycol-containing residue is derived from a polymer or a salt thereof having the following structure:

Z-(((CH 2 ) a —O) b ) c —Y

wherein Z is a reactive or non-reactive end-capped group, Y is reactive functional end group, a is from 2 to 6, b is from 2 to 10,000 and c is 1 or 2.

7 . The packaging system according to claim 6 , wherein Z is selected from the group consisting of an alkoxy group, a hydroxyl group, a glycidyl group, a thiol group and an amine group, and Y is selected from the group consisting of —X—NH 2 , —X-polydimethylsiloxane-NH 2 , —X—SH, and —X—C(O)—R′ wherein X is a linker group and R′ is hydrogen or an organic moiety comprised of 1 to 20 carbon atoms.

8 . The packaging system according to claim 5 , wherein the grafted glycosaminoglycan polymer is a reaction product of (a) a glycosaminoglycan having a polymer backbone containing reactive functionalities; and (b) a polymer comprising polyalkylene glycol chains and at least one reactive end group complementary to at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan; wherein the at least one reactive end group of the polymer forms one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan, wherein the reaction product is derived from (i) activating the glycosaminoglycan in a solution comprising one or more catalysts with an activator comprising one or more epoxyamines; and (ii) grafting the one or more side chains comprising the polyalkylene glycol-containing residue onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan by sequentially or simultaneously adding a polyol and an epoxyalcohol to the activated glycosaminoglycan.

9 . The packaging system according to claim 8 , wherein the one or more epoxyamines include both at least one amine moiety and at least one epoxide moiety.

10 . The packaging system according to claim 5 , wherein the grafted glycosaminoglycan polymer is crosslinked with one or more crosslinking agents.

11 . The packaging system according to claim 10 , wherein the one or more crosslinking agents are a bi-or polyfunctional crosslinking agent comprising two or more reactive functional groups.

12 . The packaging system according to claim 5 , wherein the aqueous packaging solution further comprises one or more comfort agents.

13 . A method of preparing a package comprising a storable, sterile ophthalmic device, the method comprising:

(a) immersing an unused ophthalmic device in an aqueous packaging solution comprising a grafted glycosaminoglycan polymer comprising a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone, wherein the aqueous packaging solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9;

(b) packaging the aqueous packaging solution and the unused ophthalmic device in a manner preventing contamination of the unused ophthalmic device by microorganisms; and

(c) sterilizing the packaged aqueous packaging solution and the unused ophthalmic device.

14 . The packaging system according to claim 5 , wherein the glycosaminoglycan is selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, hyaluronan, and hyaluronic acid or a salt thereof.

15 . The method according to claim 13 , wherein the glycosaminoglycan is selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, hyaluronan, and hyaluronic acid or a salt thereof, and the polyalkylene glycol-containing residue is derived from a polymer or a salt thereof having the following structure:

Z-(((CH 2 ) a —O) b ) c —Y

wherein Z is a reactive or non-reactive end-capped group, Y is reactive functional end group, a is from 2 to 6, b is from 2 to 10,000 and c is 1 or 2.

16 . The method according to claim 13 , wherein the grafted glycosaminoglycan polymer is a reaction product of (a) a glycosaminoglycan having a polymer backbone containing reactive functionalities; and (b) a polymer comprising polyalkylene glycol chains and at least one reactive end group complementary to at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan; wherein the at least one reactive end group of the polymer forms one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan, wherein the reaction product is derived from (i) activating the glycosaminoglycan in a solution comprising one or more catalysts with an activator comprising one or more epoxyamines; and (ii) grafting the one or more side chains comprising the polyalkylene glycol-containing residue onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan by sequentially or simultaneously adding a polyol and an epoxyalcohol to the activated glycosaminoglycan.

17 . The method according to claim 16 , wherein the one or more epoxyamines include both at least one amine moiety and at least one epoxide moiety.

18 . The method according to claim 13 , wherein the grafted glycosaminoglycan polymer is crosslinked with one or more crosslinking agents.

19 . The biomedical device according to claim 1 , wherein the one or more epoxyamines include both at least one amine moiety and at least one epoxide moiety.

20 . The biomedical device according to claim 1 , wherein the grafted glycosaminoglycan polymer is crosslinked with one or more crosslinking agents.

Assignments (8)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (065709/0253) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072460/0691 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
SECURITY INTEREST Recorded Feb 12, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066552/0041 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 29, 2023
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 065709/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2023
From: DIBELLA, JAMES ANTHONY, JR; AWASTHI, ALOK K.; RUSSELL, JADE J.; MIS, MARK R.; HAUENSTEIN, JAMES; FORNALIK, MARK; HOTELING, ANDREW J.; CONLON, SHAWN M.
To: BAUSCH HEALTH US, LLC
Reel/Frame 064829/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2023
From: BAUSCH HEALTH IRELAND LIMITED
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 064830/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2023
From: KUMAR, KAUSHLENDRA
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 064830/0035 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2023
From: BAUSCH HEALTH US, LLC
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 064829/0825 →
Continuity (3)
Division 17022398 · Sep 16, 2020
Provisional Application 62903206 · Sep 20, 2019
Related Publication 20230407077A1 · Dec 21, 2023
References Cited (85)
US 3408429A · Wichterle · 1968 [cited by applicant]
US 3660545A · Wichterle · 1972 [cited by applicant]
US 4113224A · Clark et al. · 1978 [cited by applicant]
US 4136250A · Mueller et al. · 1979 [cited by applicant]
US 4143949A · Chen · 1979 [cited by applicant]
US 4153641A · Deichert et al. · 1979 [cited by applicant]
US 4197266A · Clark et al. · 1980 [cited by applicant]
US 4312575A · Peyman et al. · 1982 [cited by applicant]
US 4555732A · Tuhro · 1985 [cited by applicant]
US 4740533A · Su et al. · 1988 [cited by applicant]
US 4758595A · Ogunbiyi et al. · 1988 [cited by applicant]
US 4910277A · Bambury et al. · 1990 [cited by applicant]
US 4954587A · Mueller · 1990 [cited by applicant]
US 5010141A · Mueller · 1991 [cited by applicant]
US 5034461A · Lai et al. · 1991 [cited by applicant]
US 5070215A · Bambury et al. · 1991 [cited by applicant]
US 5079319A · Mueller · 1992 [cited by applicant]
US 5260000A · Nandu et al. · 1993 [cited by applicant]
US 5271876A · Ibar · 1993 [cited by applicant]
US 5310779A · Lai · 1994 [cited by applicant]
US 5321108A · Kunzler et al. · 1994 [cited by applicant]
US 5358995A · Lai et al. · 1994 [cited by applicant]
US 5387662A · Kunzler et al. · 1995 [cited by applicant]
US 5449729A · Lai · 1995 [cited by applicant]
US 5464667A · Kohler et al. · 1995 [cited by applicant]
US 5512205A · Lai · 1996 [cited by applicant]
US 5573726A · Dassanayake et al. · 1996 [cited by applicant]
US 5610252A · Bambury et al. · 1997 [cited by applicant]
US 5616757A · Bambury et al. · 1997 [cited by applicant]
US 5708094A · Lai et al. · 1998 [cited by applicant]
US 5710302A · Kunzler et al. · 1998 [cited by applicant]
US 5714557A · Kunzler et al. · 1998 [cited by applicant]
US 5908906A · Kunzler et al. · 1999 [cited by applicant]
US 5955578A · Pierschbacher · 1999 [cited by examiner]
US 6884788B2 · Bulpitt et al. · 2005 [cited by applicant]
US 7981871B2 · Prestwich et al. · 2011 [cited by applicant]
US 7994356B2 · Awasthi et al. · 2011 [cited by applicant]
US 8124757B2 · Song · 2012 [cited by applicant]
US 8318695B2 · Stroumpoulis · 2012 [cited by examiner]
US 11512147B2 · Hattori et al. · 2022 [cited by applicant]
US 20080148689A1 · Xia · 2008 [cited by examiner]
US 20100204102A1 · Akiyoshi · 2010 [cited by examiner]
US 20130023658A1 · Stroumpoulis · 2013 [cited by examiner]
US 20140055741A1 · Havenstrite · 2014 [cited by examiner]
US 20160144043A1 · Tauzin · 2016 [cited by applicant]
US 20180303945A1 · Adams et al. · 2018 [cited by applicant]
US 20180371117A1 · Anseth · 2018 [cited by examiner]
US 20190106673A1 · Skardal · 2019 [cited by applicant]
US 20210087384A1 · DiBella, Jr. · 2021 [cited by applicant]
US 20210371548A1 · Hattori et al. · 2021 [cited by applicant]
US 20220257585A1 · Park et al. · 2022 [cited by applicant]
CN 101563112A · 2009 [cited by applicant]
CN 104956256A · 2015 [cited by applicant]
EP 2752704A1 · 2014 [cited by applicant]
JP 2002501211A · 2002 [cited by applicant]
JP 2004010634A · 2004 [cited by applicant]
JP 2005082915A · 2005 [cited by applicant]
JP 2006312725A · 2006 [cited by applicant]
JP 2010535277A · 2010 [cited by applicant]
JP 4987170B1 · 2012 [cited by applicant]
JP 2017025016A · 2017 [cited by applicant]
JP 2017520674A · 2017 [cited by applicant]
KR 1020160041616A · 2016 [cited by applicant]
WO 9406485A1 · 1994 [cited by applicant]
WO 9631792A1 · 1996 [cited by applicant]
WO 9935520A1 · 2002 [cited by applicant]
WO 2006053164A2 · 2006 [cited by applicant]
WO 2008079522A1 · 2008 [cited by applicant]
WO 2008136536A1 · 2008 [cited by applicant]
WO 2012014180A1 · 2012 [cited by applicant]
WO 2015048988A1 · 2015 [cited by applicant]
WO 2014035912A1 · 2015 [cited by applicant]
WO 2019098393A1 · 2020 [cited by applicant]
Japanese Patent Application No. 2022-518380 Office Action mailed Mar. 5, 2025, 4 pages. [cited by applicant]
Lai, Yu-Chin, “The Role of Bulky Polysiloxanylalkyl Methacryates in Polyurethane-Polysiloxane Hydrogels,” Journal of Applied Polymer Science, 1996, pp. 1193-1199, vol. 60. [cited by applicant]
A.T. Bell, “Chemical Reaction in Nonequilibrium Plasmas”, Proc. Intl. Conf. Phenom. Ioniz. Gases, 1977, pp. 19-33. [cited by applicant]
J. M. Tibbitt et al., “A Model for the Kinetics of Plasma Polymerization”, Macromolecules, 1977, 3, pp. 648-653. [cited by applicant]
M. Tibbitt et al., “Structural Characterization of Plasma-Polymerized Hydrocarbons”, J. Macromol. Sci.-Chem., 1976, A10, pp. 1623-1648. [cited by applicant]
C. P. Ho, et al., “Ultrathin coating of plasma polymer of methane applied on the surface of silicone contact lenses”, Mater. Res., 1988, 22, 919-937. [cited by applicant]
H. Kobayashi et al., “Plasma Polymerization of Saturated and Unsaturated Hydrocarbons”, Macromolecules, 1974, 3, pp. 277-283. [cited by applicant]
H. Yasuda et al., “Polymerization of Organic Compounds in an Electroless Glow Discharge. VI. Acetylene with Unusual Co-monomers”, J. of Appl. Poly. Sci., 1975, 19, pp. 2845-2858. [cited by applicant]
Moriyama et al., “Hyaluronic acid grafted with poly(ethylene glycol) as a novel peptide formulation”, Journal of Controlled Release, May 1, 1999, vol. 59 No. 1, pp. 77-86. [cited by applicant]
Cho-K-Y et al., “Release of ciprofloxacin from polyoxamer-graft-hyaluronic acid hydrogels in vitro”, International Journal of Pharmaceutics, Jan. 1, 2003, Jan. 1, 2003, vol. 260, pp. 83-91. [cited by applicant]
Japanese Patent Application No. 2022-518380 Office Action mailed Aug. 28, 2024, 4 pages. [cited by applicant]
Japanese Patent Application No. 2025-104382 Office Action mailed Mar. 13, 2026, 6 pages. [cited by applicant]